Evidence map›Paper›PMID 37463858›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2023

Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease.

Kritib Bhattarai, Sivaraman Rajaganapathy, Trisha Das, Yejin Kim, Yongbin Chen, Alzheimer’s Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, Qiying Dai, Xiaoyang Li, Xiaoqian Jiang and 1 more

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Advances in neural information processing systems · 2024
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kritib BhattaraiLuther College, Decorah, Iowa, USA.
Sivaraman RajaganapathyMayo Clinic, Rochester, Minnesota, USA.
Trisha DasUniversity of Illinois Urbana-Champaign, Champaign, Illinois, USA.
Yejin KimUniversity of Texas Health Science Center, Houston, Texas, USA.ORCID 0000-0001-7815-6310
Yongbin ChenMayo Clinic, Rochester, Minnesota, USA.
Alzheimer’s Disease Neuroimaging Initiative
Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
Qiying DaiMayo Clinic, Rochester, Minnesota, USA.
Xiaoyang LiMayo Clinic, Rochester, Minnesota, USA.
Xiaoqian JiangUniversity of Texas Health Science Center, Houston, Texas, USA.ORCID 0000-0001-9933-2205
Nansu ZongMayo Clinic, Rochester, Minnesota, USA.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associationsR00GM135488 · NIGMS · MAYO CLINIC ROCHESTER · PI ZONG, NANSU · 2021 to 2023
$747k
BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associationsK99GM135488 · NIGMS · MAYO CLINIC ROCHESTER · PI ZONG, NANSU · 2020 to 2021
$108k
NIA NIH HHS U01 AG024904NIGMS NIH HHS K99 GM135488NIGMS NIH HHS R00 GM135488
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a progressive neurological disorder with no specific curative medications. Sophisticated clinical skills are crucial to optimize treatment regimens given the multiple coexisting comorbidities in the patient population.

objectiveHere, we propose a study to leverage reinforcement learning (RL) to learn the clinicians' decisions for AD patients based on the longitude data from electronic health records.

methodsIn this study, we selected 1736 patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. We focused on the two most frequent concomitant diseases-depression, and hypertension, thus creating 5 data cohorts (ie, Whole Data, AD, AD-Hypertension, AD-Depression, and AD-Depression-Hypertension). We modeled the treatment learning into an RL problem by defining states, actions, and rewards. We built a regression model and decision tree to generate multiple states, used six combinations of medications (ie, cholinesterase inhibitors, memantine, memantine-cholinesterase inhibitors, hypertension drugs, supplements, or no drugs) as actions, and Mini-Mental State Exam (MMSE) scores as rewards.

resultsGiven the proper dataset, the RL model can generate an optimal policy (regimen plan) that outperforms the clinician's treatment regimen. Optimal policies (ie, policy iteration and Q-learning) had lower rewards than the clinician's policy (mean -3.03 and -2.93 vs. -2.93, respectively) for smaller datasets but had higher rewards for larger datasets (mean -4.68 and -2.82 vs. -4.57, respectively).

conclusionsOur results highlight the potential of using RL to generate the optimal treatment based on the patients' longitude records. Our work can lead the path towards developing RL-based decision support systems that could help manage AD with comorbidities.

Indexed as

Alzheimer DiseaseArtificial IntelligenceCholinesterase InhibitorsHumansLearningMemantineCholinesterase InhibitorsMemantineactionAlzheimer’s diseasepolicypolicy iterationQ-learningreinforcement learningrewardtreatment learning

Identifiers

PMID37463858
PMCPMC10531148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.